Cargando…

The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients

OBJECTIVE: The purpose of this study was to determine the cost-utility of treating anemic dialysis patients with continuous erythropoietin receptor activator (CERA) once monthly or Epoetin Beta (EpoB) thrice weekly compared with a reference strategy of managing anemia with red blood cell transfusion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maoujoud, Omar, Ahid, Samir, Cherrah, Yahia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771395/ https://www.ncbi.nlm.nih.gov/pubmed/26966386 http://dx.doi.org/10.2147/IJNRD.S96027

Ejemplares similares

The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients
por: Maoujoud, Omar, et al.
Publicado: (2015)

The Coronavirus Disease 2019 (COVID-19) Pandemic in Africa: What Can We Expect?
por: Maoujoud, Omar, et al.
Publicado: (2020)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2017)

Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
por: Beiraghdar, Fatemeh, et al.
Publicado: (2015)

Cost-effectiveness of continuous erythropoietin receptor activator in anemia
por: Schmid, Holger
Publicado: (2014)

Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial
por: Uriol-Rivera, Miguel G., et al.
Publicado: (2021)

Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis
por: Oh, Jieun, et al.
Publicado: (2014)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Anemia and blood transfusion in the critically ill patient: role of erythropoietin
por: Corwin, Howard L
Publicado: (2004)

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial
por: Woodland, Andrea L., et al.
Publicado: (2017)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010
por: Ghanname, Imane, et al.
Publicado: (2014)

Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
por: Galli, Luca, et al.
Publicado: (2015)

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience
por: Kacarska - Fotevska, Isidora Isidora, et al.
Publicado: (2020)

Transfusion-dependent anaemia treatment using continuous erythropoietin receptor activator (epoetin β pegol) and roxadustat after darbepoetin treatment failure in low-risk myelodysplastic syndrome: a case report
por: Ikenoue, Tatsuyoshi, et al.
Publicado: (2021)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
por: Davis-Ajami, Mary Lynn, et al.
Publicado: (2014)

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
por: Macpherson, Iain RJ, et al.
Publicado: (2009)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016)

Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study
por: El Hamdouni, Mariam, et al.
Publicado: (2019)

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia
por: Zhu, Yifan, et al.
Publicado: (2022)

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis
por: Picon, Paulo D., et al.
Publicado: (2014)

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience
por: Kacarska-Fotevska, Isidora, et al.
Publicado: (2019)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
por: Ohashi, Naro, et al.
Publicado: (2012)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient
por: Munie, Stephanie, et al.
Publicado: (2021)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
por: Gilbertson, David T, et al.
Publicado: (2013)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure
por: Jöbsis, Jasper J., et al.
Publicado: (2010)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
por: Santos, E.J.F., et al.
Publicado: (2018)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Impact of inflammation on anemia of hemodialysis patients who were under treatment of recombinant human erythropoietin
por: Rafiean-Kopaie, Mahmoud, et al.
Publicado: (2013)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
por: London, Gérard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s127po00uavqg77fsromlkjqen